TP53 mutations and relevance of expression of TP53 pathway genes in paediatric acute myeloid leukaemia.
David G J CucchiCosta BachasKim KleinSander HuttenhuisChristian M ZwaanGert J OssenkoppeleJeroen M W M JanssenGertjan L KaspersJacqueline CloosPublished in: British journal of haematology (2019)
Limited data are available on the incidence and impact of TP53 alterations and TP53 pathway deregulation in paediatric acute myeloid leukaemia (AML). We analysed TP53 alterations in bone marrow samples of 229 patients with de novo paediatric AML, and detected heterozygous missense exon mutations in two patients (1%) and 17p deletions of the TP53 gene in four patients (2%). These patients more frequently had complex karyotype (50% vs. 4%, P = 0·002) or adverse cytogenetic abnormalities, including complex karyotype (67% vs. 17%, P = 0·013), compared to TP53 wild-type. Differential expression of TP53 pathway genes was associated with poor survival, indicating a role for TP53 regulators and effector genes.
Keyphrases
- end stage renal disease
- bone marrow
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- genome wide
- intensive care unit
- emergency department
- dendritic cells
- prognostic factors
- mesenchymal stem cells
- liver failure
- immune response
- dna methylation
- patient reported outcomes
- gene expression
- autism spectrum disorder
- allogeneic hematopoietic stem cell transplantation
- copy number
- early onset
- intellectual disability
- electronic health record
- long non coding rna
- adverse drug